Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation

Bone Marrow Transplantation volume 51, pages 1313–1317 (2016)Cite this article

Subjects

Abstract

In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologous-SCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an anti-GVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012; 30: 2183–2189.

    Article  CAS  Google Scholar 

  2. Kaloyannidis P, Voutiadou G, Baltadakis I, Tsirigotis P, Spyridonidis A, Repousis P et al. Outcomes of Hodgkin’s lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 451–457.

    Article  Google Scholar 

  3. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97: 310–317.

    Article  Google Scholar 

  4. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano Classification. J Clin Oncol 2014; 32: 3059–3067.

    Article  Google Scholar 

  5. Gopal A, Ramchandren R, O’Connor O, Berryman RB, Advani RH, Chen R et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012; 120: 560–568.

    Article  CAS  Google Scholar 

  6. Carlo-Stella C, Ricci F, Dalto S, Mazza R, Malagola M, Patriarca F et al. Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. Oncologist 2015; 20: 323–328.

    Article  CAS  Google Scholar 

  7. Robinson S, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94: 230–238.

    Article  Google Scholar 

  8. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455–462.

    Article  CAS  Google Scholar 

  9. Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin’s lymphoma. J Clin Oncol 2011; 29: 971–978.

    Article  CAS  Google Scholar 

  10. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al. Nonmyeloablative stem cell transplantat on is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12: 172–183.

    Article  Google Scholar 

  11. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience. Haematologica 2008; 93: 257–264.

    Article  CAS  Google Scholar 

  12. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS et al. Donor leukocyte infusions (DLIs) in recurrent Hodgkin lymphoma (HL) following allogeneic stem cell transplantation: ten-year experience at the M.D. Anderson Cancer Center. Leuk Lymphoma 2012; 53: 1239–1241.

    Article  Google Scholar 

  13. Chen Y, McDonough S, Hasserjian R, Chen H, Coughlin E, Illiano C et al. Expression of CD30 in patients with acute graft-versus-host disease. Blood 2012; 120: 691–696.

    Article  CAS  Google Scholar 

  14. Theurich S, Malcher J, Wennhold K, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol 2013; 31: e59–e63.

    Article  Google Scholar 

Download references

Acknowledgements

We thank our patients and families for their trust and patience.

Author information

Author notes

  1. I Danylesko and A Nagler: These authors contributed equally to this work.

Authors and Affiliations

  1. Second Department of Internal Medicine, ATTIKO University Hospital, National and Kapodistrian University of Athens, Athens, Greece

    P Tsirigotis, K Gkirkas & M Stamouli

  2. Hematology Division, Chaim Sheba Medical Center, Tel Aviv, Israel

    I Danylesko, N Shem-Tov, R Yerushalmi, A Avigdor, G Goldstein, A Shimoni & A Nagler

  3. Bone Marrow Transplantation Unit, University of Patras, Patras, Greece

    A Spyridonidis

  4. Bone Marrow Transplantation Unit, University of Lille, Lille, France

    J Gauthier

  5. Bone Marrow Transplantation and Hematology & Lymphoma Department, Evaggelismos General Hospital, Athens, Greece

    J Apostolidis

  6. Department of Hematology, Hospital St Antoine, Paris, France

    M Mohty

Authors
  1. P Tsirigotis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Danylesko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Gkirkas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Shem-Tov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Yerushalmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Stamouli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Avigdor
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Spyridonidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Gauthier
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Apostolidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Shimoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Tsirigotis.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsirigotis, P., Danylesko, I., Gkirkas, K. et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 51, 1313–1317 (2016). https://doi.org/10.1038/bmt.2016.129

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.129

This article is cited by

Search

Advanced search

Quick links